ALT vs XOMA

ALT exhibits severe financial distress despite strong revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating poor operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics (ROE: -50.57%, ROA: -28.17%), massive operating losses, and negative earnings suggest high distress risk. While revenue growth is explosive at 420% YoY, this is not translating into profitability or cash flow, and the stock trades at an extreme Price/Sales of 10,690.50, reflecting speculative valuation. Analysts recommend 'buy' with a $17.22 target, but this is likely driven by pipeline optimism rather than fundamentals. The technical trend is bearish, and insider activity is neutral, offering no conviction.

XOMA exhibits a stark divergence between deterministic value metrics and market momentum. With a weak Piotroski F-Score of 3/9 and a current price ($37.89) trading significantly above its Graham Number ($15.24) and Intrinsic Value ($10.22), the stock is fundamentally overvalued by traditional standards. However, exceptional profit margins (60.81%) and strong YoY revenue growth (57.9%) support a growth narrative, further bolstered by a high analyst target of $65.75. The overall profile is that of a high-risk, high-reward royalty play with poor traditional health scores but strong operational efficiency.